Psychedelics Archives - Page 25 of 68

2 minute read

Promising Milestone: FDA Approves California-Based Trial Assessing MDMA For Schizophrenia

June 12, 3:48 PM

The FDA has approved a clinical trial that will assess PharmAla Biotech Holdings' (OTC: PMBHF) proprietary LaNeo Investigational Medical Product (IMP) 40mg MDMA capsules for the treatment of schizophrenia. This is the first time these capsules will be tried on humans in the U.S

PMBHF

2 minute read

Awakn To Focus On R&D Of Addiction Therapies, Moves Away From Ketamine Treatment For Alcoholism

By Lara Goldstein

June 12, 3:18 PM

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) is set to exit ketamine healthcare services to focus solely on research and development of therapeutics to treat addiction and licensing of its intellectual property (IP.)

AWKNF

2 minute read

BetterLife’s Non-Hallucinogenic LSD’s Clinical Studies, Braxia’s Psychedelic Treatments Continue

By Lara Goldstein

June 9, 4:45 PM

Psychedelics biotech BetterLife Pharma (OTCQB: BETRF) announced its non-hallucinogenic LSD derivative, BETR-001, is progressing through IND-enabling studies toward expected clinical studies targeting Major Depressive Disorder (MDD.)

BETRF

2 minute read

Creso Pharma’s LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia

By Lara Goldstein

June 9, 2:27 PM

Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTCMKTS: COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr.

COPHF

3 minute read

AI-Powered Psychedelic Treatments: Special Status And Next-Gen Contests Winners

By Lara Goldstein

June 8, 5:25 PM

As psychedelics and AI travel their own development paths, here are some initiatives looking at ways of enhancing the former with the latter’s help.

CGNSF

3 minute read

MA, FL And OH Psychedelics Scientists And Educators’ Latest Research And Views

By Lara Goldstein

June 8, 9:44 AM

Along with a growing scientific corpus supporting the therapeutic potential of psychedelics, several states and most noticeably Massachusetts are seeing the decriminalization of natural substances via local measures.

PSYBF

2 minute read

Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More

By Lara Goldstein

June 6, 10:57 AM

Major Investor Commits $30 Million To Psychedelics Funding

CYBN

1 minute read

Lucy Scientific Goes After Pasithea Therapeutics Common Shares For A ‘142% Premium’ Deal

By Lara Goldstein

June 5, 6:01 PM

Health Canada-licensed psychedelics producer Lucy Scientific Discovery (NASDAQ: LSDI) announced it has sent a proposal to biotech business Pasithea Therapeutics Corp.

KTTA

4 minute read

Disney, Amgen, First Republic, Psychedelics: How One CEO’s Universal Deal-Making Approach Shapes Industries

By Benzinga Cannabis

June 5, 5:59 PM

In the dynamic world of business, adaptability is king, a principle veteran executive Richard Nanula has embodied throughout his career. "Every place I've been... maybe you could conclude that they might not fit because one of them didn't have much relation to the other.

KTTA

1 minute read

Numinus’ Clinical Arm To Lead Enrollment Site For MindMed’s Phase 2b LSD Study

By Lara Goldstein

June 5, 4:27 PM

Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b stud

CMPS